Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ENOVIS CORPORATION

(ENOV)
  Report
Delayed Nyse  -  01:03 2022-11-25 pm EST
55.46 USD   +0.85%
11/18Enovis : Credit Agreement - Form 8-K
PU
11/18Enovis Corp : Other Events (form 8-K)
AQ
11/17Enovis Introduces New Orthopedic Implant for Hindfoot Fusion Surgeries
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Enovis Completes Acquisition of Insight Medical Systems

07/06/2022 | 08:02am EST

Transaction Expands Enabling Technologies Platform for Enovis’ Reconstructive Portfolio with Augmented Reality Surgical Guidance Technology

WILMINGTON, DE, July 06, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, announced that it has acquired Insight Medical Systems, a technology company dedicated to reimagining orthopedic surgical guidance. Insight’s flagship solution, ARVIS®, is the only FDA-cleared augmented reality solution precisely engineered for the specific needs of hip and knee replacement surgery. Financial terms of the transaction were not disclosed.

“We are excited to welcome Insight’s talented team to our Enovis family where we will work together to improve patient outcomes through the use of next generation augmented reality surgical guidance in orthopedic surgery,” said Matt Trerotola, CEO of Enovis. “Adding Insight’s technology to our rapidly growing Surgical business advances our enabling technologies platform with innovation tailored to today’s healthcare economics and especially the ASC.”

Since Enovis’ initial investment in Insight Medical Systems in 2020 and a follow-on funding round in 2021, the company received 510(k) FDA clearance for the ARVIS® Augmented Reality System and successfully completed over 200 cases in the U.S.

“ARVIS delivers real-time, hands-free surgical guidance at the point of care and is designed to generate measurably better patient outcomes in a streamlined, space-conserving and cost-effective manner compared to traditional robotic offerings,” explains Brady Shirley, COO of Enovis. “Simply put, the ARVIS Augmented Reality System represents the next era of orthopedic technology, and we look forward to expanding its features and reach while integrating additional joint replacement surgery capabilities in the future.”

ARVIS will be commercially available in Q3 of 2022 and the Insight™ team will become part of the Enovis Surgical organization (previously DJO Surgical) with the goal of driving further growth and expansion of the company’s orthopedic enabling technologies platform.

ABOUT ENOVIS™

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.


All news about ENOVIS CORPORATION
11/18Enovis : Credit Agreement - Form 8-K
PU
11/18Enovis Corp : Other Events (form 8-K)
AQ
11/17Enovis Introduces New Orthopedic Implant for Hindfoot Fusion Surgeries
MT
11/17Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions
GL
11/17Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions
AQ
11/17Enovis Corporation Announces Introduction of DynaNail Helix
CI
11/16ESAB Secondary Common Stock Offering Priced at $40 Per Share
MT
11/14ESAB Says Former Parent Enovis Launches Secondary Offering; Shares Fall
MT
11/10Enovis' ARVIS« Awarded the AAHKS Industry Innovation Award at the 2022 American Academy..
GL
11/03Baird Adjusts Enovis' Price Target to $68 From $73, Keeps Outperform Rating
MT
More news
Analyst Recommendations on ENOVIS CORPORATION
More recommendations
Financials (USD)
Sales 2022 1 570 M - -
Net income 2022 68,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 60,1x
Yield 2022 -
Capitalization 3 003 M 3 003 M -
Capi. / Sales 2022 1,91x
Capi. / Sales 2023 1,81x
Nbr of Employees 16 200
Free-Float 88,7%
Chart ENOVIS CORPORATION
Duration : Period :
Enovis Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENOVIS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 55,46 $
Average target price 60,57 $
Spread / Average Target 9,22%
EPS Revisions
Managers and Directors
Matthew L. Trerotola Chief Executive Officer & Director
Brady R. Shirley Chief Operating Officer
Christopher Michael Hix Chief Financial Officer & Executive Vice President
Mitchell P. Rales Non-Executive Chairman
Rajiv Vinnakota Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOVIS CORPORATION-29.85%3 003
STRYKER CORPORATION-12.97%88 076
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.-17.15%13 402
SMITH & NEPHEW PLC-14.69%11 598
INSPIRE MEDICAL SYSTEMS, INC.0.10%6 653
AXONICS, INC.17.32%3 254